2018: Briefing note on NIH proposed license to Gilead for CD-30 CAR T technology

Contact: Kim Treanor 202-332-2670; kim.treanor@keionline.org January 5, 2018 The National Institutes of Health (NIH) has proposed an exclusive license with Gilead for certain patent applications for inventions that target CD-30 proteins and CAR T technologies. The proposed license is to… Continue Reading

2018: NIH Prospective Grant of an Exclusive Patent License to ElevateBio for CAR T cancer treatment

The following are comments by KEI, UACT, Social Security Works, HealthGap, Public Citizen, Dr. Ophira Ginsbug and James Love on an NIH proposed exclusive license for patents on a CAR T technology for “Treatment of FMS-Like Tyrosine Kinase 3 (FLT3)… Continue Reading

NIH Preparing to License CAR Treatment Patents to Investors Behind Sovaldi and Soliris

In a recent Federal Register notice, the National Institutes of Health (NIH) has announced its intent to grant an exclusive patent license on chimeric antigen receptor (CAR) therapies for the treatment of certain cancers to ElevateBio, a company located in… Continue Reading

WIPO side event, December 6, 2018, on the Implications of Article 27.3(a) of the WTO TRIPS Agreement on the patentability of gene and cell-based therapies

DATE: Thursday, 6 December 2018 TIME: 1:30 PM to 3 PM VENUE: Room B CONVENER: Knowledge Ecology International (KEI) Knowledge Ecology International (KEI) cordially invites you to attend our side event during negotiations of the 29th Session of the Standing… Continue Reading

Pfizer’s efforts to block Colombia’s accession to the OECD in 2017-2018

The following PDF file includes several email exchanges between Pfizer and USTR regarding Colombia’s accession to the Organisation for Economic Co-operation and Development (OECD). Pfizer proposed several conditions it wanted Colombia to agree to before the US would withdraw objections… Continue Reading

Pfizer asked USTR to block Malaysia requirement on drug price transparency. September 2017

KEI has received Pfizer and USTR emails and a Pfizer briefing memo to USTR from September 2017, asking the USTR to block a Malaysia Requirement to disclose drug prices. The documents were obtained under a Freedom of Information request to… Continue Reading

Communications between Gilead and USTR regarding Malaysia compulsory license on HCV patents, 2017 to May 2018

The attached document is a 78 page PDF file obtained from USTR under the Freedom of Information Act (copy here), regarding communications between Gilead and USTR, over Malaysia’s decision to grant a compulsory license on patents for HCV treatments. This… Continue Reading

Roadblocks ahead on the WHO Roadmap on Access to Medicines and Vaccines?

By Katy Athersuch [1] and Thiru Balasubramaniam In May 2018, the World Health Assembly (WHA) adopted decision WHA71(8) requesting WHO’s Director-General to “elaborate a roadmap, in consultation with Member States, outlining the programming of WHO’s work on access to medicines… Continue Reading

Comments on NIH Prospective Exclusive License on Diabetes Treatments

Update. NIH sent us a 147 word response on November 23, 2018: NIH to KEI regarding Ovensa 23 NOV 2018. The brief reply states that “Prior to posting notices of a proposed grant of exclusive commercialization licenses, the NIH determines… Continue Reading